Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment
T cell lymphoma (TCL) is a highly heterogeneous group of diseases with a poor prognosis and low 5-year overall survival rate. The current therapeutic regimens have relatively low efficacy rates. Clinical studies of single-target chimeric antigen receptor T cell (CAR-T cell) therapy in T lymphocytes...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2023-09-01
|
| Seri Bilgileri: | Molecular Therapy: Oncolytics |
| Konular: | |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S2372770523000542 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|